Deliver the Upcoming Phase 1B/2A Trial of their Synthetic Cannabinoid, ART27.13
Aptus Clinical has been appointed full service clinical CRO partner by Artelo Biosciences Inc. (through their fully owned UK subsidiary, Trinity R&D Ltd.) to deliver the upcoming Phase 1B/2A trial of their synthetic cannabinoid, ART27.13. This latest agreement builds on an earlier research and development partnership agreement, where Aptus successfully designed and supported the critical path pre-clinical experiments and completed key clinical strategy and planning activities for Artelo.
Andrew Yates, ART27.13 Project Director at Trinity R&D, said, “We are delighted with the progress that this project has made in transitioning through the discovery phase and into preparation for clinical testing in just 16 months. The depth and breadth of experience that our Aptus colleagues have brought to this project and their flexible collaborative approach has been key in helping us achieve this significant project milestone for ART27.13. We look forward to continuing to work with Aptus and our investigators in testing the clinical utility of ART27.13 in patients with cancer associated weight loss.”
Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, commented, “Aptus Clinical have proved themselves to be a true partner with us on the ART27.13 project. They have approached the inevitable challenges associated with any drug project in a fully supportive and flexible way with a total focus on doing the right things to move the project forward. We look forward to continuing our collaboration Aptus on this next phase of the ART27.13 journey.
Steve McConchie, Chief Executive Officer of Aptus Clinical, added, “Cancer related anorexia affects about 60% of advanced cancer patients and is an area where new treatment options are desperately needed. As a full-service Clinical CRO focused on transforming promising projects into valued medicines we are honoured to have been selected to deliver a trial that is so important for both Artelo and patients with cancer.”
Additional Information
About Aptus Clinical
Aptus Clinical Limited is a UK based, clinical contract research organisation, that specialises in the design, conduct and delivery of early phase clinical studies with a particular focus in oncology, rare diseases, cell and gene therapies. Projects are delivered by a team of highly experienced drug development experts utilising their extensive network of academic and hospital links. Aptus are partners in iMATCH, the Innovate UK funded Manchester-based Advanced Therapy Centre Hub and are suppliers to the Cell and Gene Therapy Catapult. For more information, visit www.aptusclinical.com and Twitter @aptusclinical
About ART27.13
ART27.13 is a highly potent peripherally selective synthetic dual cannabinoid agonist believed to target peripheral cannabinoid receptors sending a feeding message to the brain. The combined Phase 1b/2a trial is expected to run approximately 12 months and enrol up to 49 subjects at clinical sites within the United Kingdom. The study is designed to determine the most effective and well tolerated dose in cancer patients and evaluate activity using criteria such as weight gain, lean body mass, and improvement of anorexia.
About Artelo Biosciences
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio
